IL95327A - Composition for the treatment of cardiac and of vascular hypertrophy and hyperplasia - Google Patents

Composition for the treatment of cardiac and of vascular hypertrophy and hyperplasia

Info

Publication number
IL95327A
IL95327A IL9532790A IL9532790A IL95327A IL 95327 A IL95327 A IL 95327A IL 9532790 A IL9532790 A IL 9532790A IL 9532790 A IL9532790 A IL 9532790A IL 95327 A IL95327 A IL 95327A
Authority
IL
Israel
Prior art keywords
alkyl
carbon atoms
aryl
optionally substituted
propyl
Prior art date
Application number
IL9532790A
Other languages
English (en)
Other versions
IL95327A0 (en
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6386970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL95327(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of IL95327A0 publication Critical patent/IL95327A0/xx
Publication of IL95327A publication Critical patent/IL95327A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/556Angiotensin converting enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preliminary Treatment Of Fibers (AREA)
  • Crucibles And Fluidized-Bed Furnaces (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Element Separation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL9532790A 1989-08-11 1990-08-09 Composition for the treatment of cardiac and of vascular hypertrophy and hyperplasia IL95327A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3926606A DE3926606A1 (de) 1989-08-11 1989-08-11 Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie

Publications (2)

Publication Number Publication Date
IL95327A0 IL95327A0 (en) 1991-06-30
IL95327A true IL95327A (en) 1995-10-31

Family

ID=6386970

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9532790A IL95327A (en) 1989-08-11 1990-08-09 Composition for the treatment of cardiac and of vascular hypertrophy and hyperplasia

Country Status (22)

Country Link
US (1) US5231083A (cs)
EP (1) EP0417473B1 (cs)
JP (1) JP3452199B2 (cs)
KR (1) KR0185969B1 (cs)
AT (1) ATE94409T1 (cs)
AU (1) AU631914B2 (cs)
CA (1) CA2023089C (cs)
CS (1) CS277644B6 (cs)
DD (1) DD297063A5 (cs)
DE (2) DE3926606A1 (cs)
DK (1) DK0417473T3 (cs)
ES (1) ES2059931T3 (cs)
FI (1) FI903936A7 (cs)
HU (1) HU205008B (cs)
IE (1) IE64604B1 (cs)
IL (1) IL95327A (cs)
NO (1) NO306979B1 (cs)
NZ (1) NZ234836A (cs)
PH (1) PH30831A (cs)
PL (1) PL286442A1 (cs)
PT (1) PT94957B (cs)
ZA (1) ZA906327B (cs)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0682947T3 (da) 1994-05-19 1998-05-04 Mitsubishi Chem Corp Medikament til terapeutisk og profylaktisk behandling af sygdomme forårsaget af glatmuskelcelle-hyperplasi
SG68529A1 (en) * 1995-05-25 1999-11-16 Univ Singapore The use of des-aspartate-angiotensin i (agr-val-tyr-ile-his-pro-phe-his-leu) as an anti-cardiac hypertrophic agent
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
CN1268331C (zh) * 1999-08-30 2006-08-09 萨诺费-阿文蒂斯德国有限公司 肾素-血管紧张素系统抑制剂在制备预防心血管疾病的药物中的用途
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
EP1817007A2 (en) * 2004-11-05 2007-08-15 King Pharmaceuticals Research and Development Inc. Stabilized individually coated ramipril particles, compositions and methods
US8980924B2 (en) 2010-11-24 2015-03-17 The Trustees Of Columbia University In The City Of New York Non-retinoid RBP4 antagonist for treatment of age-related macular degeneration and stargardt disease
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
WO2014151959A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
ES2700541T3 (es) 2013-03-14 2019-02-18 Univ Columbia Octahidrociclopentapirroles, su preparación y uso
EP3495357B1 (en) 2013-03-14 2021-05-05 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
US9434727B2 (en) 2014-04-30 2016-09-06 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4311705A (en) * 1980-10-06 1982-01-19 E. R. Squibb & Sons, Inc. Carboxyalkanoyl and hydroxycarbamoylalkanoyl derivatives of substituted prolines
US4337201A (en) * 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US4381297A (en) * 1981-05-04 1983-04-26 E. R. Squibb & Sons, Inc. Substituted carbonyl phosphinyl-alkanoyl compounds
US4602002A (en) * 1983-02-07 1986-07-22 Merck & Co., Inc. N-carboxymethyl substituted lysyl and α-(ε-aminoalkyl) glycyl amino acid antihypertensive agents
US4548941A (en) * 1984-07-30 1985-10-22 Merck & Co., Inc. 1,5-Methano-1H-4-benzazonine dicarboxylates, process for preparing and use as calcium blockers
US4587253A (en) * 1984-07-30 1986-05-06 Merck & Co., Inc. Bridged pyridine compounds useful as calcium channel blockers and analgesics
US4599341A (en) * 1984-10-01 1986-07-08 Merck & Co., Inc. Substituted and bridged pyridines useful as calcium channel blockers
US4656188A (en) * 1985-10-09 1987-04-07 Merck & Co., Inc. Ace inhibitors in macular degeneration
DE3705220A1 (de) * 1987-02-19 1988-09-01 Boehringer Ingelheim Kg Mittel zur behandlung von coronarerkrankungen oder organischem hirnsyndrom
ZA896851B (en) * 1988-09-14 1990-06-27 Hoffmann La Roche Use of ace-inhibitors

Also Published As

Publication number Publication date
NO903532L (no) 1991-02-12
IL95327A0 (en) 1991-06-30
NO903532D0 (no) 1990-08-10
HU205008B (en) 1992-03-30
AU631914B2 (en) 1992-12-10
ATE94409T1 (de) 1993-10-15
IE64604B1 (en) 1995-08-23
US5231083A (en) 1993-07-27
NO306979B1 (no) 2000-01-24
FI903936A7 (fi) 1991-02-12
CA2023089A1 (en) 1991-02-12
CS277644B6 (en) 1993-03-17
ZA906327B (en) 1991-05-29
JP3452199B2 (ja) 2003-09-29
DK0417473T3 (da) 1993-12-13
ES2059931T3 (es) 1994-11-16
NZ234836A (en) 1997-05-26
DD297063A5 (de) 1992-01-02
IE902910A1 (en) 1991-02-27
AU6092090A (en) 1991-02-14
PH30831A (en) 1997-10-17
EP0417473A1 (de) 1991-03-20
KR0185969B1 (ko) 1999-05-01
CA2023089C (en) 2003-01-14
DE59002721D1 (de) 1993-10-21
FI903936A0 (fi) 1990-08-09
PT94957A (pt) 1991-05-22
CS395890A3 (en) 1992-08-12
HU904966D0 (en) 1991-01-28
EP0417473B1 (de) 1993-09-15
JPH0383957A (ja) 1991-04-09
KR910004189A (ko) 1991-03-28
DE3926606A1 (de) 1991-02-14
PT94957B (pt) 1997-05-28
HUT54504A (en) 1991-03-28
PL286442A1 (en) 1992-03-09

Similar Documents

Publication Publication Date Title
JP3003995B2 (ja) 高血圧治療用医薬組成物
US5256687A (en) Pharmaceutical composition for the treatment of high blood pressure
KR930008094B1 (ko) 안기오텐신 전환효소 억제제의 제조방법
US5231083A (en) Method for the treatment of cardiac and of vascular hypertrophy and hyperplasia
US5403856A (en) Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors
US5231080A (en) Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease
US5684016A (en) Method of treating cardiac insufficiency
CA1332350C (en) Combination of angiotensin converting enzyme inhibitors with potassium channel modulators and use thereof in pharmaceuticals
US5231084A (en) Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons
DE3610391A1 (de) Verbindungen mit nootroper wirkung, diese enthaltende mittel und deren verwendung bei der behandlung und prophylaxe cognitiver dysfunktionen
JPH01246222A (ja) 向精神作用を有する化合物およびそれらを含有する薬剤
KR940010032B1 (ko) 고혈압 치료용 약제학적 조성물의 제조방법
KR900003321B1 (ko) 인식보조작용이 있는 화합물, 이를 함유하는 제제 및 인식 기능 장애를 치료하고 예방하는데 있어서 이의 용도
HK1006148A1 (en) Use of a combination of an ace inhibitor with a calcium antagonist in the treatment of proteinuria
HK1006148B (en) Use of a combination of an ace inhibitor with a calcium antagonist in the treatment of proteinuria

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
HP Change in proprietorship
KB Patent renewed
KB Patent renewed